The expression of MiR۱۴۳-۳p on the MCF۷ and MDA-MB۲۳۱ cell lines after being treated with Epirubcin

Epirubicin, a widely used chemotherapeutic agent in breast cancer treatment, has demonstrated modifying efficacy across different molecular subtypes. This study surveies, the effects of epirubicin on miR-۱۴۳-۳p expression and apoptotic pathways in MCF-۷ (luminal) and MDA-MB-۲۳۱ (triple-negative) breast cancer cell lines. Cell viability was appraisaled by utilizing MTT assays, while apoptosis was evaluated through flow cytometry and Western blot analysis of Bax and Bcl-۲ proteins. MiR-۱۴۳-۳p expression was quantified using qRT-PCR. Results indicated a dose- and time-dependent cytotoxic effect of epirubicin on both cell lines, with MCF-۷ cells exhibiting higher sensitivity (IC۵۰: ۰.۴۴ μg/mL at ۲۴h, ۰.۱۱ μg/mL at ۴۸h) compared to MDA-MB-۲۳۱ cells (IC۵۰: ۴.۴۰ μg/mL at ۲۴ h, ۲.۹۴ μg/mL at ۴۸h). Flow cytometry unfolded remarkable enhancement in apoptotic cell populations following epirubicin treatment. Western blot analysis confirmed apoptosis induction via the mitochondrial pathway, with upregulation of Bax and downregulation of Bcl-۲ proteins. Notably, qRT-PCR analysis exhibited notable increasing regulations of miR-۱۴۳-۳p expression in both cell lines after epirubicin treatment, with a more pronounced effect in MCF-۷ cells. These findings offer that miR-۱۴۳-۳p may play a essentional role in modifying the response to epirubicin in breast cancer cells, potentially serving as a biomarker for chemotherapy efficacy and also can induce apoptotic . The differential response between luminal and triple-negative subtypes underscores the importance of personalized treatment strategies in breast cancer management. Further investigation into miR-۱۴۳-۳p's role could lead to novel therapeutic approaches and improved patient outcomes.Future studies should focus on validating miR-۱۴۳-۳p as a predictive biomarker for chemotherapy response and exploring therapeutic strategies to restore its function in cancer cells. By integrating such biomarkers into clinical practice, it may be possible to enhance treatment efficacy and minimize resistance, ultimately improving patient outcomes in breast cancer theraputic . but more studies are needed.

کلیدواژه ها:

miR-۱۴۳-۳p ، epirubicin ، breast cancer ، apoptosis ، drug resistance